Cutaneous T-Cell Lymphoma Risk Elevated in Dupilumab-Treated Patients With Atopic Dermatitis

Strategic Insights -

Research presented from Memorial Sloan-Kettering Cancer Center highlights the potential association between the use of dupilumab, a monoclonal antibody inhibiting interleukin-4 receptor alpha (IL-4Ra) and interleukin-13 receptor (IL-13R), and the development of cutaneous T-cell lymphoma (CTCL) in patients with atopic dermatitis (AD). The study's authors emphasize that while the risk is rare, it is crucial to differentiate CTCL from AD and other inflammatory skin disorders, and to investigate the role of IL-13 and its receptors in CTCL.

Key Takeaways:

  • The study, supported by NIH National Cancer Institute (NCI), investigated the association between dupilumab use and CTCL in patients with AD.
  • The research found a potential association between dupilumab use and developing CTCL in patients with AD, although the risk is considered rare.
  • The study's authors provide practical clinical care recommendations for the use of dupilumab in patients with AD, CTCL, and non-skin lymphomas.
  • The research highlights the need for further studying alternative diagnostic approaches to differentiate CTCL from AD and other inflammatory skin disorders.
  • The authors suggest that IL-4Ra/IL-13R inhibition may play a role in unmasking pre-existing malignant T cell clones through increased IL-13 availability.

Statistics:

  • The study reports a rare association between dupilumab use and CTCL in patients with AD.
  • The research emphasizes the need for further investigation into the roles of IL-13 and its receptors in CTCL.
  • The study's authors highlight the importance of differentiating CTCL from AD and other inflammatory skin disorders.
  • According to the news editors, the study found no evidence to support the direct oncogenic risk of transforming AD into lymphoma by dupilumab treatment.

Sources:

  • Cutaneous T Cell Lymphoma Following Dupilumab Therapy In Patients With Atopic Dermatitis: Clinical Review and Recommendations. American Journal of Clinical Dermatology, 2025.
  • NewsRx. Data on Cutaneous T-Cell Lymphoma Reported by Researchers at Memorial Sloan-Kettering Cancer Center (Cutaneous T Cell Lymphoma Following Dupilumab Therapy In Patients With Atopic Dermatitis: Clinical Review and Recommendations). Hematology Week. June 16, 2025; p 991.
  • Memorial Sloan-Kettering Cancer Center.
  • American Journal of Clinical Dermatology.
  • National Cancer Institute (NCI).